S1252 Presentation and Long Term Follow-Up of Refractory Celiac Disease (RCD): Comparison of Rcd of Type I with Rcd of Type II
Georgia Malamut(Délégation Paris 5), Christophe Cellier(Assistance Publique – Hôpitaux de Paris), Pauline Afchain, Anne Lavergne‐Slove, Nadine Cerf–Bensussan(Université Paris Cité), Jean‐Frédéric Colombel(Mount Sinai Hospital), Nicole Brousse(Hôpital Necker-Enfants Malades), Jacques Cosnes(Assistance Publique – Hôpitaux de Paris), Matthieu Allez(Inserm), Olivier Hermine(Centre National de la Recherche Scientifique), Yoram Bouhnik(Clinique Ambroise Paré), Elizabeth Macintyre(Inserm), Diane Damotte(Inserm), Thierry Lecomte(Université Paris Cité), Dominique Cazals‐Hatem(Hôpital Saint-Louis), Virginie Verkarre(Université Paris Cité), Jean‐Charles Delchier(Assistance Publique – Hôpitaux de Paris), Bertrand Meresse(Centre Hospitalier Universitaire de Lille)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k